Ignyta (Ignyta) Tax Provision : $0.00 Mil (TTM As of Sep. 2017)

View and export this data going back to 2014. Start your Free Trial

What is Ignyta Tax Provision?

Ignyta's tax provision for the three months ended in Sep. 2017 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2017 was $0.00 Mil.

Ignyta Tax Provision Historical Data

The historical data trend for Ignyta's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ignyta Tax Provision Chart

Ignyta Annual Data

Trend

Aug12

Aug13

Dec14

Dec15

Dec16

Tax Provision

-0.01

Ignyta Quarterly Data
	Nov12	Feb13	May13	Aug13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Ignyta Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Ignyta (Ignyta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ignyta Inc (NAS:RXDX) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ignyta.com

Ignyta is an oncology biotechnology company. Its research is targeting tumor reduction and cancer treatment through both integrated therapeutic and companion diagnostics. The integrated therapeutic segment aims to discover, develop, and commercialize molecularly targeted therapies. The companion diagnostic segment aims to pair the discovered therapies with biomarker-based companion diagnostics to precisely identify, at the molecular level, patients likely to have good results. The company's portfolio includes compounds to treat adult patient populations for solid tumors, pediatric patients with advanced solid tumor malignancies, and patients with superficial and nodular basal cell carcinoma.

Executives

James L Freddo	director	3115 MERRYFIELD ROW, SAN DIEGO CA 92121
Steven L. Hoerter	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Pratik S Multani	officer: Chief Medical Officer	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Jonathan E Lim	director, 10 percent owner, officer: President, CEO & Director	11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121
Heinrich Dreismann	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jacob Chacko	officer: Chief Financial Officer	C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Igor Bilinsky	officer: GM, Immuno-Oncology/SVP Sp Ops	C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Matthew Onaitis	officer: General Counsel and Secretary	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Adrian Senderowicz	officer: Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024

Ignyta (Ignyta) Headlines

From GuruFocus

Steven Cohen Dives Deeper Into Health Care

By Graham Griffin Graham Griffin • 03-23-2021